Hepatitis C Trial, Recruiting (NCT07419347)

Hepatitis C Trial, Recruiting NCT07419347 Sponsor: AbbVie Condition: Hepatitis C

Printed from Voxsanity (voxsanity.com.au) — NCT07419347 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Hepatitis C

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who have been prescribed an 8-week course of the medication Glecaprevir/Pibrentasvir (also known as G/P).
People who have not yet received any treatment for their current infection (note: people who had a previous infection that was treated and resolved are still considered untreated for a new current infection, as long as no treatment has been given for this current infection).
People who are currently taking one or more other prescription medications or using illicit drugs at the same time as their G/P treatment.

Who may not be able to join:

People who are being treated with other antiviral medications (called DAAs) that are not G/P.
People who have a history of advanced liver disease where the liver has stopped functioning properly (known as decompensated cirrhosis).
People who have had a Hepatitis B virus (HBV) infection.
People who have had a type of liver cancer called hepatocellular carcinoma (HCC).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 27 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ABBVIE INC., AbbVie

Phone: +1 847-935-8741

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07419347

Sponsor: AbbVie

Phase: Not Applicable

Status: Recruiting

Condition: Hepatitis C

Trial contact: +1 847-935-8741

More information: https://clinicaltrials.gov/study/NCT07419347

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who have been prescribed an 8-week course of the medication Glecaprevir/Pibrentasvir (also known as G/P).
People who have not yet received any treatment for their current infection (note: people who had a previous infection that was treated and resolved are still considered untreated for a new current infection, as long as no treatment has been given for this current infection).
People who are currently taking one or more other prescription medications or using illicit drugs at the same time as their G/P treatment.

Who may not be able to join:

People who are being treated with other antiviral medications (called DAAs) that are not G/P.
People who have a history of advanced liver disease where the liver has stopped functioning properly (known as decompensated cirrhosis).
People who have had a Hepatitis B virus (HBV) infection.
People who have had a type of liver cancer called hepatocellular carcinoma (HCC).

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 27 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

AbbVie

Registry

ClinicalTrials.gov

Start date

27 February 2026

Est. completion

1 June 2026

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Percentage of Participants Experiencing Adverse Events; Percentage of Participants Experiencing On-Treatment Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 5x Upper Limit of Normal (ULN); Percentage of Participants Experiencing On-Treatment Alanine aminotransferase (ALT) or Aspartate Aminotransferase (AST) > 3x Upper Limit of Normal (ULN) With Total Bilirubin > 2x ULN

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov